Segnalazione JAK/STAT
Gli inibitori della segnalazione JAK/STAT sono composti che interrompono la via della Janus chinasi (JAK) e del trasduttore e attivatore della trascrizione (STAT), coinvolta nella segnalazione delle citochine, nella crescita cellulare e nella risposta immunitaria. Questi inibitori sono strumenti importanti per studiare la regolazione di questa via e il suo ruolo in diverse malattie, tra cui tumori, disturbi immunitari e condizioni infiammatorie. Gli inibitori JAK/STAT sono anche in fase di sviluppo come terapie mirate per queste malattie. Presso CymitQuimica, offriamo un'ampia selezione di inibitori di alta qualità della segnalazione JAK/STAT per supportare la tua ricerca in biologia molecolare, oncologia e immunologia.
Sottocategorie di "Segnalazione JAK/STAT"
Trovati 322 prodotti di "Segnalazione JAK/STAT"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formula:C19H11Cl2N5Colore e forma:SolidPeso molecolare:380.23BP-5-087
CAS:<p>BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.</p>Formula:C36H30F8N2O6SColore e forma:SolidPeso molecolare:770.69Galiellalactone
CAS:<p>inhibits IL-6-mediated JAK/STAT signal transduction</p>Formula:C11H14O3Purezza:98%Colore e forma:SolidPeso molecolare:194.23CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formula:C15H21N5O2Colore e forma:SolidPeso molecolare:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formula:C21H18ClF2N7O3Colore e forma:SolidPeso molecolare:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formula:C18H23BrN4O2Colore e forma:SolidPeso molecolare:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formula:C23H22F5N7OColore e forma:SolidPeso molecolare:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formula:C15H19N5OColore e forma:SolidPeso molecolare:285.34YM-341619
CAS:<p>YM-341619 (AS1617612), potent STAT6 inhibitor; IC50: 0.70 nM; hinders IL-4-induced Th2 in mice; may aid allergic disease research.</p>Formula:C22H21F3N6O2Colore e forma:SolidPeso molecolare:458.44TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formula:C22H25F2N5O2Colore e forma:SolidPeso molecolare:429.46Stafia-1-dipivaloyloxymethyl ester
CAS:<p>Stafia-1 suppresses pSTAT5a in a dose-dependent manner (0-200 μM) without affecting pSTAT5b.</p>Formula:C37H48FO13PColore e forma:SolidPeso molecolare:750.74MM-206
CAS:<p>MM-206, a cell-permeable, non-cytotoxic naphthalene sulfonamide compound, it effectively inhibits STAT3 DNA-binding activity.</p>Formula:C22H12F5NO3S2Colore e forma:SolidPeso molecolare:497.46MC0704
<p>MC0704: STAT3 inhibitor, IC50=2.13μM, promotes apoptosis & cell arrest, anti-breast cancer, for mTNBC research.</p>Formula:C29H21BrN4O2Colore e forma:SolidPeso molecolare:537.41STAT3-IN-15
<p>STAT3-IN-15: Potent, oral STAT3 inhibitor for IPF, blocks STAT3 phosphorylation, cell migration, and EMT.</p>Formula:C20H17F3N2O3SColore e forma:SolidPeso molecolare:422.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formula:C28H28ClN5O4SColore e forma:SolidPeso molecolare:566.07HJC0149
CAS:<p>HJC0149 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.</p>Formula:C15H10ClNO4SColore e forma:SolidPeso molecolare:335.76TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formula:C18H17N5O3SColore e forma:SolidPeso molecolare:383.42SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formula:C24H26N8O3Colore e forma:SolidPeso molecolare:474.52PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formula:C18H26N6OColore e forma:SolidPeso molecolare:342.44LLL12
CAS:<p>LLL12 inhibits STAT3 phosphorylation, boosting Cisplatin and Paclitaxel effects against ovarian cancer cell activities.</p>Formula:C14H9NO5SColore e forma:SolidPeso molecolare:303.29JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formula:C20H18FN5O3SPurezza:99.53%Colore e forma:SolidPeso molecolare:427.45JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Formula:C26H30ClN7O2Colore e forma:SolidPeso molecolare:508.02JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formula:C25H28N8OPurezza:97.89%Colore e forma:SolidPeso molecolare:456.54JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Formula:C19H26N8SPurezza:98%Colore e forma:SolidPeso molecolare:398.53JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Formula:C20H18ClN7OPurezza:98%Colore e forma:SolidPeso molecolare:407.86AZD-1897
CAS:<p>AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.</p>Formula:C18H23N3O3SPurezza:99.49%Colore e forma:SolidPeso molecolare:361.46M-110
CAS:<p>M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).</p>Formula:C22H28ClN5O3Purezza:99.55%Colore e forma:SolidPeso molecolare:445.94JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Formula:C26H32FN9O2Purezza:98%Colore e forma:SolidPeso molecolare:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formula:C25H32N8O2Purezza:99.64% - 99.87%Colore e forma:SolidPeso molecolare:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formula:C22H28N6O2Purezza:99.72%Colore e forma:SolidPeso molecolare:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formula:C18H15FN4O3Purezza:98.61% - 99.81%Colore e forma:SolidPeso molecolare:354.34Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formula:C12H12N4O5Colore e forma:SolidPeso molecolare:292.25PIM-1 Inhibitor 2
CAS:PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.Formula:C17H11ClN4OPurezza:98.81%Colore e forma:SolidPeso molecolare:322.75JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formula:C22H23FN4O3SPurezza:98.4%Colore e forma:SolidPeso molecolare:442.51STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formula:C15H15ClN4O2Purezza:99.01%Colore e forma:SolidPeso molecolare:318.76Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formula:C22H26N8Purezza:99.82%Colore e forma:SolidPeso molecolare:402.50JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Formula:C21H21N5O2Purezza:99.59%Colore e forma:SolidPeso molecolare:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formula:C29H32Cl2N2O5SPurezza:99.51% - 99.83%Colore e forma:SoildPeso molecolare:591.55NT219
CAS:NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.Formula:C16H14BrNO5SPurezza:98.06% - 99.72%Colore e forma:SolidPeso molecolare:412.26Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurezza:99.82%Colore e forma:SolidPeso molecolare:389.4Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purezza:99.85%Colore e forma:SolidPeso molecolare:355.39PM-43I
CAS:<p>PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.</p>Formula:C38H50F2N3O10PColore e forma:SolidPeso molecolare:777.79JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purezza:98%Colore e forma:SolidPeso molecolare:420.46TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formula:C27H25F3N4O4Purezza:99.39% - ≥98%Colore e forma:SolidPeso molecolare:526.51STAT3-IN-14
CAS:<p>STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .</p>Formula:C14H10O5Colore e forma:SolidPeso molecolare:258.23Pim-1 kinase inhibitor 5
CAS:<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Formula:C22H13Cl2N3OPurezza:98%Colore e forma:SolidPeso molecolare:406.26JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Colore e forma:SolidPeso molecolare:367.44JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formula:C17H19F2N7OSPurezza:98%Colore e forma:SolidPeso molecolare:407.44PIM1-IN-4
CAS:<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Formula:C27H25BrCl2CuN6OPurezza:98%Colore e forma:SolidPeso molecolare:663.88JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:380.44GNE-955
CAS:<p>GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).</p>Formula:C22H24N8OPurezza:98%Colore e forma:SolidPeso molecolare:416.48PIM1-IN-1
CAS:<p>PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.</p>Formula:C25H30N8O2Purezza:98%Colore e forma:SolidPeso molecolare:474.56Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Colore e forma:SolidPeso molecolare:416.43Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Formula:C42H70O12Purezza:98.46% - 99.13%Colore e forma:SolidPeso molecolare:767Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purezza:98%Colore e forma:SolidPeso molecolare:602.521JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purezza:98%Colore e forma:SolidPeso molecolare:379.37Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purezza:98%Colore e forma:SolidPeso molecolare:383.41JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurezza:98%Colore e forma:SolidPeso molecolare:466.341Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Colore e forma:SolidPeso molecolare:527.66JAK2-IN-4
CAS:<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Formula:C23H27N5O4SPurezza:98%Colore e forma:SolidPeso molecolare:469.56JAK-IN-5
CAS:JAK-IN-5 is a JAK inhibitor.Formula:C27H31FN6OPurezza:98.1% - 99.37%Colore e forma:SolidPeso molecolare:474.57STAT3 degrader-2
CAS:<p>STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and various</p>Formula:C59H62N9O13PPurezza:98%Colore e forma:SolidPeso molecolare:1136.15TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Colore e forma:SolidPeso molecolare:376.74JAK-IN-31
CAS:<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Formula:C21H19N7O2S2Purezza:98%Colore e forma:SolidPeso molecolare:465.55QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formula:C26H27N7O3Purezza:98%Colore e forma:SolidPeso molecolare:485.54Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColore e forma:SolidPeso molecolare:505.01FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purezza:98%Colore e forma:SolidPeso molecolare:442.523JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Colore e forma:SolidPeso molecolare:684.69ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formula:C24H28N4O5Purezza:98%Colore e forma:SolidPeso molecolare:452.5PIM-IN-2
CAS:<p>PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .</p>Formula:C19H22N4O2Purezza:98%Colore e forma:SolidPeso molecolare:338.4STAT6-IN-1
CAS:<p>STAT6-IN-1: STAT6 inhibitor, IC50=0.028 µM, targets SH2 domain, for allergy and cancer research.</p>Formula:C33H37IN3O7PColore e forma:SolidPeso molecolare:745.54FD1024
CAS:<p>FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.</p>Formula:C21H20F2N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:430.47HS94
CAS:<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Formula:C15H15N5O2SPurezza:95.04%Colore e forma:SolidPeso molecolare:329.38JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formula:C18H20N4O3Purezza:98.04% - 98.19%Colore e forma:SolidPeso molecolare:340.38JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formula:C16H13IN6Colore e forma:SolidPeso molecolare:416.22GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formula:C20H18F2N6O5SColore e forma:SolidPeso molecolare:492.46Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formula:C19H19F2N7O3Colore e forma:SolidPeso molecolare:431.40YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formula:C32H34F3N7O2Colore e forma:SolidPeso molecolare:605.65JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formula:C29H25N7O6SColore e forma:SolidPeso molecolare:599.62Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColore e forma:SolidPeso molecolare:422.37STAT3-IN-7
CAS:<p>STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.</p>Formula:C30H26F5N5O4SColore e forma:SolidPeso molecolare:647.62JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Colore e forma:SolidJAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formula:C23H22Cl2N4OColore e forma:SolidPeso molecolare:441.35TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formula:C24H20FN7O4Colore e forma:SolidPeso molecolare:489.458iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formula:C19H15F3N2O2Colore e forma:SolidPeso molecolare:360.33JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formula:C22H17FN6O2SPurezza:98%Colore e forma:SolidPeso molecolare:448.47AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Formula:C17H14FN5OColore e forma:SolidPeso molecolare:323.32AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formula:C17H13ClFN5OColore e forma:SolidPeso molecolare:357.77Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formula:C25H24N6O3S2Purezza:98%Colore e forma:SolidPeso molecolare:520.63(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurezza:98%Colore e forma:SolidPeso molecolare:312.37SI-109
CAS:<p>SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.</p>Formula:C40H44F2N7O9PPurezza:98%Colore e forma:SolidPeso molecolare:835.79(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formula:C20H27ClN6OColore e forma:SolidPeso molecolare:402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formula:C20H15ClF3N3OSColore e forma:SolidPeso molecolare:437.87JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formula:C31H31F3N8O4Colore e forma:SolidPeso molecolare:639.64PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formula:C31H31FN8O2Purezza:98%Colore e forma:SolidPeso molecolare:566.63lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formula:C16H25N5OSColore e forma:SolidPeso molecolare:335.468JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formula:C17H20N6OPurezza:98.81%Colore e forma:SolidPeso molecolare:324.38LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Colore e forma:SolidPeso molecolare:473.57AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Formula:C20H28FN7Purezza:98%Colore e forma:SolidPeso molecolare:385.48Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formula:C20H20N4O2SColore e forma:SolidPeso molecolare:380.463Prohibitin ligand 1
<p>Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.</p>Formula:C20H22N2OColore e forma:SolidPeso molecolare:306.4GDC-0339
CAS:GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formula:C20H22F3N7OSColore e forma:SolidPeso molecolare:465.5CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formula:C18H16ClN5OColore e forma:SolidPeso molecolare:353.806JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formula:C26H36FN5O2Colore e forma:SolidPeso molecolare:469.59CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formula:C18H18N4Colore e forma:SolidPeso molecolare:290.36Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Formula:C28H31F2N7O4SPurezza:98.64% - 99.56%Colore e forma:SolidPeso molecolare:599.65Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Colore e forma:SolidPeso molecolare:443.46Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColore e forma:SolidPeso molecolare:429.47Pim-1 kinase inhibitor 6
CAS:Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Formula:C21H10BrCl2N3Colore e forma:SolidPeso molecolare:455.13Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColore e forma:SolidPeso molecolare:426.42JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formula:C17H23N7OColore e forma:SolidPeso molecolare:341.41JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formula:C23H23N5O2Colore e forma:SolidPeso molecolare:401.46Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formula:C24H25N7O2Colore e forma:SolidPeso molecolare:443.50JDTic
CAS:<p>JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.</p>Formula:C28H39N3O3Colore e forma:SolidPeso molecolare:465.63(3R,4S)-Tofacitinib
CAS:<p>(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.</p>Formula:C16H20N6OPurezza:98%Colore e forma:SolidPeso molecolare:312.37JAK2-IN-9
CAS:<p>Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.</p>Formula:C20H24N6O2SPurezza:98%Colore e forma:SolidPeso molecolare:412.51Ref: TM-T79581
Prodotto fuori produzioneJAK-IN-27
CAS:<p>JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM</p>Formula:C20H21F2N7OPurezza:98%Colore e forma:SolidPeso molecolare:413.42JAK1-IN-10
CAS:<p>JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].</p>Formula:C15H17N7Purezza:98%Colore e forma:SolidPeso molecolare:295.34JAK-IN-34
CAS:<p>JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,</p>Formula:C27H26N6OPurezza:98%Colore e forma:SolidPeso molecolare:450.53STAT3-IN-18
CAS:<p>STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and</p>Formula:C18H24Cl2N2O6PtPurezza:98%Colore e forma:SolidPeso molecolare:630.38JAK1-IN-11
CAS:<p>JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.</p>Formula:C26H36N6O4SPurezza:98%Colore e forma:SolidPeso molecolare:528.67DPP
CAS:<p>DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating</p>Formula:C36H40Cl2N2O10PtPurezza:98%Colore e forma:SolidPeso molecolare:926.7
